Near-term business remains in choppy waters
31/01/25 -"Despite a >10% reduction in our target price, as detailed in the EPS section, we continue to see significant upside potential for Carl Zeiss Meditec. This is supported by the company's strong ..."
Pages
65
Language
English
Published on
31/01/25
You may also be interested by these reports :
13/10/26
Demant reported robust preliminary Q3 sales figures, driven by strong demand for its newly launched hearing aids. The 2026 guidance has been revised ...
09/10/26
Our target price has been revised downwards due to updated estimates following management’s decision to lower the upper end of its topline guidance ...
08/10/26
Our target price has increased due to a higher NAV and DCF, along with a 20% premium applied to our peer-based valuation metrics, excluding dividend ...
08/10/26
The TP increase reflects upgrades to our DCF and NAV (discussed above). The investment case remains compelling: consumables-led growth, the ...